Beta bionics announces pricing of upsized $204 million initial public offering

Irvine, calif., jan. 29, 2025 (globe newswire) -- beta bionics, inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. the gross proceeds to beta bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by beta bionics, are expected to be $204.0 million. in addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from beta bionics and 1,325,000 shares from the selling stockholders named in the prospectus. beta bionics will not receive any proceeds from any sale of shares by the selling stockholders.
BBNX Ratings Summary
BBNX Quant Ranking